[go: up one dir, main page]

PE20001028A1 - PIPERIDINE DERIVATIVES - Google Patents

PIPERIDINE DERIVATIVES

Info

Publication number
PE20001028A1
PE20001028A1 PE1999000886A PE00088699A PE20001028A1 PE 20001028 A1 PE20001028 A1 PE 20001028A1 PE 1999000886 A PE1999000886 A PE 1999000886A PE 00088699 A PE00088699 A PE 00088699A PE 20001028 A1 PE20001028 A1 PE 20001028A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
cyclodecil
alcoxyl
piperidin
Prior art date
Application number
PE1999000886A
Other languages
Spanish (es)
Inventor
Andrea Cesura
Jurgen Wichmann
Stephan Rover
Torsten Hoffmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20001028A1 publication Critical patent/PE20001028A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE PIPERIDINA DE FORMULA I, DONDE R1 ES TETRAHIDRONAFTILO, (CH2)nC6H5R4; n ES 0-4; R4 ES H, ALQUILO, ALCOXILO, CICLOALQUILO C5-C12 OPCIONALMENTE SUSTITUIDO POR ALQUILO; R2 ES H, OH, ALCOXILO, ALQUENILOXILO, ALQUILO; R3 ES CICLOALQUILO C5-C7, FENILO OPCIONALMENTE SUSTITUIDO CON OH, HALOGENO, ALCOXILO, ALQUENILOXILO, ALQUILO, O-(CH2)n-C6H5; n ES 0-3. SON COMPUESTOS PREFERIDOS (3RS,4RS)-1-CICLONONIL-4-(2-HIDROXI-FENIL)PIPERIDIN-3-OL; 1-CICLODECIL-4-(2-METOXI-FENIL)-PIPERIDINA, (3RS,4RS)-1-CICLODECIL-4-(2-ISOPROPIL-FENIL)PIPERIDIN-3-OL), 2-(1-CICLODECIL-PIPERIDIN-4-IL)FENOL, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN AGONISTA-ANTAGONISTA DEL RECEPTOR ORFANINA FQ (OFQ), POR LO QUE PUEDE SER UTIL PARA TRATAMIENTO DE DEFICITS DE MEMORIA, ATENCION, TRASTORNOS PSIQUIATRICOS, NEUROLOGICOS, FISIOLOGICOSREFERS TO PIPERIDINE COMPOUNDS OF FORMULA I, WHERE R1 IS TETRAHYDRONAPHTHYL, (CH2) nC6H5R4; n IS 0-4; R4 IS H, ALKYL, ALCOXYL, CYCLOALKYL C5-C12 OPTIONALLY REPLACED BY ALKYL; R2 IS H, OH, ALCOXYL, ALKENYLOXYL, ALKYL; R3 IS C5-C7 CYCLOALKYL, PHENYL OPTIONALLY SUBSTITUTED WITH OH, HALOGEN, ALCOXYL, ALKENYLOXYL, ALKYL, O- (CH2) n-C6H5; n IS 0-3. PREFERRED COMPOUNDS ARE (3RS, 4RS) -1-CYCLONONYL-4- (2-HYDROXY-PHENYL) PIPERIDIN-3-OL; 1-CYCLODECIL-4- (2-METOXY-PHENYL) -PIPERIDINE, (3RS, 4RS) -1-CYCLODECIL-4- (2-ISOPROPYL-PHENYL) PIPERIDIN-3-OL), 2- (1-CYCLODECIL-PIPERIDIN -4-IL) PHENOL, AMONG OTHERS. IT ALSO REFERS TO A PROCEDURE FOR PREPARATION. COMPOUND I IS AN AGONIST-ANTAGONIST OF THE ORPHANINE FQ RECEPTOR (OFQ), SO IT MAY BE USEFUL FOR THE TREATMENT OF MEMORY DEFICITS, ATTENTION, PSYCHIATRIC, NEUROLOGICAL, PHYSIOLOGICAL DISORDERS

PE1999000886A 1998-09-07 1999-09-02 PIPERIDINE DERIVATIVES PE20001028A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98116852 1998-09-07

Publications (1)

Publication Number Publication Date
PE20001028A1 true PE20001028A1 (en) 2000-10-12

Family

ID=8232585

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000886A PE20001028A1 (en) 1998-09-07 1999-09-02 PIPERIDINE DERIVATIVES

Country Status (14)

Country Link
EP (1) EP1109786A1 (en)
JP (1) JP2002524446A (en)
KR (1) KR20010073115A (en)
CN (1) CN1316994A (en)
AR (1) AR022083A1 (en)
AU (1) AU5858199A (en)
BR (1) BR9913106A (en)
CA (1) CA2343168A1 (en)
CO (1) CO5150201A1 (en)
MA (1) MA26683A1 (en)
PE (1) PE20001028A1 (en)
TR (1) TR200100660T2 (en)
WO (1) WO2000014067A1 (en)
ZA (1) ZA200101830B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2157148B1 (en) * 1998-11-18 2002-03-01 Faes Fabrica Espanola De Produ NEW 4-SUBSTITUTED PIPERIDINS.
JP4056977B2 (en) 2002-03-29 2008-03-05 田辺三菱製薬株式会社 Sleep disorder drug
JP2005289816A (en) 2002-05-14 2005-10-20 Banyu Pharmaceut Co Ltd Benzimidazole derivatives
ITMI20031349A1 (en) * 2003-07-01 2005-01-02 Ufpeptides S R L ANTAGONISTS OF THE NOP RECEPTOR AND THEIR THERAPEUTIC USES.
ITFE20060036A1 (en) * 2006-11-23 2008-05-24 Ufpeptides Srl NOP RECEPTOR AGONISTS FOR THE TREATMENT OF DISCINESIA FROM LEVODOPA
CN101547923A (en) 2006-12-07 2009-09-30 弗·哈夫曼-拉罗切有限公司 Spiro-piperidine derivatives as VIA receptor antagonists
CN101541797A (en) 2006-12-07 2009-09-23 弗·哈夫曼-拉罗切有限公司 Spiro-piperidine derivatives
KR20090078367A (en) 2006-12-08 2009-07-17 에프. 호프만-라 로슈 아게 Indole
WO2008068184A1 (en) 2006-12-08 2008-06-12 F. Hoffmann-La Roche Ag Indoles which act as via receptor antagonists
EP2097376A2 (en) 2006-12-22 2009-09-09 F. Hoffmann-Roche AG Spiro-piperidine derivatives
CN101671293B (en) * 2009-10-12 2012-01-11 南开大学 Alpha-glycosidase inhibitor compound in silkworm excrement total alkaloid and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132710A (en) * 1976-12-20 1979-01-02 Ayerst, Mckenna And Harrison, Ltd. [2]Benzopyrano[3,4-c]pyridines and process therefor
FI792076A7 (en) * 1978-07-05 1981-01-01 Ciba Geigy Ag Process for the preparation of novel phenylpiperidine derivatives.
DE3614907A1 (en) * 1986-05-02 1987-11-05 Basf Ag N-SUBSTITUTED PYRROLIDONE AND PIPERIDINE DERIVATIVES AND THEIR SALTS
WO1991009594A1 (en) * 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
GB9100505D0 (en) * 1991-01-10 1991-02-20 Shell Int Research Piperidine derivatives
WO1993000313A2 (en) * 1991-06-27 1993-01-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
CA2226058C (en) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives

Also Published As

Publication number Publication date
CO5150201A1 (en) 2002-04-29
TR200100660T2 (en) 2001-06-21
KR20010073115A (en) 2001-07-31
EP1109786A1 (en) 2001-06-27
AU5858199A (en) 2000-03-27
BR9913106A (en) 2001-05-08
MA26683A1 (en) 2004-12-20
JP2002524446A (en) 2002-08-06
CN1316994A (en) 2001-10-10
CA2343168A1 (en) 2000-03-16
WO2000014067A1 (en) 2000-03-16
ZA200101830B (en) 2002-06-05
AR022083A1 (en) 2002-09-04

Similar Documents

Publication Publication Date Title
PE20001028A1 (en) PIPERIDINE DERIVATIVES
DE69433955D1 (en) 2- (1- (1,3-thiazolin-2-yl) azetidin-3-yl) thio-carbapenem derivatives
EP0940387A4 (en) PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONISTS, PROCESSES AND INTERMEDIATES THEREOF
PE20091884A1 (en) SELECTED CGRP ANTAGONISTS, PROCEDURE FOR THEIR PREPARATION, AS WELL AS THEIR USE AS A MEDICINE
BR9508375A (en) Heterocyclic tachykinin receptor antagonist
NO882258D0 (en) PROCEDURE FOR THE PREPARATION OF NEW CYCLEIC AMINE DERIVATIVES.
PE59999A1 (en) DERIVATIVES OF 1,3,8-TRIAZA-ESPIRO [4,5] DECAN-4-ONA-8-SUBSTITUTED
PE20021072A1 (en) DERIVATIVES OF DIHYDRO-BENZO (b) (1,4) -DIAZEPIN-2-ONA AS ANTAGONISTS I OF mGLUR2
PT957080E (en) NEW ETHYLAMINE DERIVATIVES
DE69613710D1 (en) BENZOXAZEPINE COMPOUNDS, THEIR PRODUCTION AND USE AS A LIPID Sinker
YU50002A (en) Substituted piperidines, medicaments containing these compounds,and methods for the production thereof
US20040242592A1 (en) 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors
PE20050442A1 (en) DERIVATIVES OF 8-AZONIABICICLO [3.2.1] OCTANE AS ANTAGONISTS OF MUSCARINE ACETYLCHOLINE RECEPTORS
DK478788D0 (en) POLYMORF MODIFICATION OF THE COMPOUND 8- (4- (4- (2-PYRIMIDINYL) -1-PIPERAZINYL) BUTYL) -8-AZASPIRO- (4.5) DECAN-7,9-DION
HU9202449D0 (en) Method for producing substituted 2-amino-1,2,3,4-tetrahydro-naphtaline derivatives and 3-chromane ones thereof
DE69617226D1 (en) Piperidine.
DE60125656D1 (en) Fluorescent lamp cover and lighting device
MX12708A (en) OXIMA DERIVATIVES OF 1,2,5,6-TETRAHYDROPYRIDINE AND PROCEDURE FOR ITS PREPARATION
NZ535170A (en) Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
AR019197A1 (en) COMPOSITES DERIVED FROM PIPERIDINE ANTIHISTAMINICS, INTERMEDIATE COMPOUNDS, PROCEDURE FOR PREPARATION OF PIPERIDINE DERIVATIVES AND PROCEDURES FOR THE PREPARATION OF INTERMEDIARIES.
MY136065A (en) Prodrugs to nmda receptor ligands
DK0979822T3 (en) Process for the preparation of 2-carbamoyl-pyridines
HU0204401D0 (en) Process for producing 2,6-dichlorophenol derivatives
IT1226301B (en) PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR THE SYNTHESIS OF DILTIAZEM.
ATE362784T1 (en) PHARMACEUTICAL PREPARATION CONTAINING PALLADIUM COMPLEX COMPOUNDS

Legal Events

Date Code Title Description
FC Refusal